- Home
- WOLF vs SLS Comparison
WOLF vs SLS Comparison
Compare WOLF & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOLF
- SLS
- Stock Information
- Founded
- WOLF 1987
- SLS 2012
- Country
- WOLF United States
- SLS United States
- Employees
- WOLF N/A
- SLS N/A
- Industry
- WOLF Semiconductors
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- WOLF Technology
- SLS Health Care
- Exchange
- WOLF Nasdaq
- SLS Nasdaq
- Market Cap
- WOLF 200.8M
- SLS 169.6M
- IPO Year
- WOLF 1993
- SLS N/A
- Fundamental
- Price
- WOLF $1.55
- SLS $1.78
- Analyst Decision
- WOLF Hold
- SLS Strong Buy
- Analyst Count
- WOLF 13
- SLS 1
- Target Price
- WOLF $10.67
- SLS $7.00
- AVG Volume (30 Days)
- WOLF 154.0M
- SLS 4.0M
- Earning Date
- WOLF 08-20-2025
- SLS 08-12-2025
- Dividend Yield
- WOLF N/A
- SLS N/A
- EPS Growth
- WOLF N/A
- SLS N/A
- EPS
- WOLF N/A
- SLS N/A
- Revenue
- WOLF $761,300,000.00
- SLS N/A
- Revenue This Year
- WOLF N/A
- SLS N/A
- Revenue Next Year
- WOLF $14.42
- SLS N/A
- P/E Ratio
- WOLF N/A
- SLS N/A
- Revenue Growth
- WOLF N/A
- SLS N/A
- 52 Week Low
- WOLF $0.39
- SLS $0.77
- 52 Week High
- WOLF $3.33
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- WOLF 49.56
- SLS 50.48
- Support Level
- WOLF $1.38
- SLS $1.85
- Resistance Level
- WOLF $1.77
- SLS $2.09
- Average True Range (ATR)
- WOLF 0.44
- SLS 0.15
- MACD
- WOLF 0.06
- SLS -0.03
- Stochastic Oscillator
- WOLF 35.38
- SLS 15.22
About WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.